Journal of Medicinal Chemistry · 2022 · 73 citations · 37 references
PharmacyMedicinal ChemistryOncologyCancer PharmacologyDrug DiscoveryMolecular OncologyCancer ProteomicsCyclin-dependent KinasesDna Damage SignalingMolecular Tumor ProfilingProteomic ProfilingTargeted Cancer TherapyAntiproliferative AgentsAntiproliferative Drug ActionCdk InhibitorsDna Damage Response InhibitorsDna Damage Response PathwaysTarget-ligand SelectivityTherapeutic Cyclin-dependent Kinase InhibitionTriple-negative Breast Cancer Therapy
, suggesting the potential advantage of a CDK12/13 degrader for TNBC targeted therapy.
37
Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation
Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text
Medicine, Oncology, Pharmacology +16
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Tamotsu Yoshimori, Akira Yamamoto, Yoshinori Moriyama et al. · Journal of Biological Chemistry · 1991 · 1.4K citations · Full text
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Susan D. Demo, Christopher J. Kirk, Monette Aujay et al. · Cancer Research · 2007 · 675 citations · Full text
Medicine, Oncology, Pharmacology +13